Pfizer Exercised its Option to License AnTolRx’s Immune Tolerance Therapy for Type 1 Diabetes (T1D)

Shots:

• Pfizer to get exclusive rights for development and commercialization of AnTolRx’s lead immunotherapeutic for T1D. AnTolRx to receive upfront, milestones & royalties on sales
• Under the June 2016 agreement, Pfizer exercised its option to license AnTolRx’s T1D candidate
• AnTolRx develops antigen-specific therapies, based on immune tolerance induction, for inflammatory and autoimmune diseases including T1D, RA, IBD, and Celiac disease

Click here to read full press release/ article | Ref: AnTolRx | Image: Twitter